JP2016185981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016185981A5 JP2016185981A5 JP2016137228A JP2016137228A JP2016185981A5 JP 2016185981 A5 JP2016185981 A5 JP 2016185981A5 JP 2016137228 A JP2016137228 A JP 2016137228A JP 2016137228 A JP2016137228 A JP 2016137228A JP 2016185981 A5 JP2016185981 A5 JP 2016185981A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain
- amino acid
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102100034577 Desmoglein-3 Human genes 0.000 claims 2
- 101000924311 Homo sapiens Desmoglein-3 Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006221230 | 2006-08-14 | ||
| JP2006221230 | 2006-08-14 | ||
| JP2007019108 | 2007-01-30 | ||
| JP2007019108 | 2007-01-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014175480A Division JP5972325B2 (ja) | 2006-08-14 | 2014-08-29 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016185981A JP2016185981A (ja) | 2016-10-27 |
| JP2016185981A5 true JP2016185981A5 (OSRAM) | 2017-04-13 |
| JP6162864B2 JP6162864B2 (ja) | 2017-07-12 |
Family
ID=39082111
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008529863A Active JP5317697B2 (ja) | 2006-08-14 | 2007-08-14 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
| JP2013043041A Active JP5651726B2 (ja) | 2006-08-14 | 2013-03-05 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
| JP2014175480A Active JP5972325B2 (ja) | 2006-08-14 | 2014-08-29 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
| JP2016137228A Active JP6162864B2 (ja) | 2006-08-14 | 2016-07-12 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008529863A Active JP5317697B2 (ja) | 2006-08-14 | 2007-08-14 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
| JP2013043041A Active JP5651726B2 (ja) | 2006-08-14 | 2013-03-05 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
| JP2014175480A Active JP5972325B2 (ja) | 2006-08-14 | 2014-08-29 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20100092457A1 (OSRAM) |
| EP (3) | EP3111955B1 (OSRAM) |
| JP (4) | JP5317697B2 (OSRAM) |
| AU (1) | AU2007285217B2 (OSRAM) |
| BR (1) | BRPI0713086A2 (OSRAM) |
| CA (1) | CA2658050A1 (OSRAM) |
| WO (1) | WO2008020586A1 (OSRAM) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2004033499A1 (ja) * | 2002-10-11 | 2006-02-09 | 中外製薬株式会社 | 細胞死誘導剤 |
| EP1710255A4 (en) * | 2003-12-12 | 2008-09-24 | Chugai Pharmaceutical Co Ltd | MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR |
| TW200530269A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
| WO2005056602A1 (ja) * | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | アゴニスト活性を有する改変抗体のスクリーニング方法 |
| WO2005056603A1 (ja) * | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | 細胞死誘導剤 |
| US20080274110A1 (en) * | 2004-04-09 | 2008-11-06 | Shuji Ozaki | Cell Death-Inducing Agents |
| US9493569B2 (en) * | 2005-03-31 | 2016-11-15 | Chugai Seiyaku Kabushiki Kaisha | Structural isomers of sc(Fv)2 |
| JPWO2006123724A1 (ja) * | 2005-05-18 | 2008-12-25 | 国立大学法人徳島大学 | 抗ｈｌａ抗体を利用した新規医薬品 |
| EP1908482B1 (en) * | 2005-06-10 | 2017-09-06 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
| KR101360671B1 (ko) | 2005-06-10 | 2014-02-07 | 추가이 세이야쿠 가부시키가이샤 | ｓｃ（Ｆｖ）２를 함유하는 의약조성물 |
| TW200808351A (en) * | 2006-07-13 | 2008-02-16 | Chugai Pharmaceutical Co Ltd | Cell death-inducing agents |
| EP3111955B1 (en) | 2006-08-14 | 2019-01-23 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |
| US8470323B2 (en) * | 2007-01-09 | 2013-06-25 | The Trustees Of The University Of Pennsylvania | Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display |
| CL2008000719A1 (es) * | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
| WO2010002862A2 (en) * | 2008-07-01 | 2010-01-07 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
| ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
| EP2308897A1 (en) * | 2009-10-09 | 2011-04-13 | Pierre Fabre Medicament | Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer |
| SG185487A1 (en) | 2010-05-11 | 2012-12-28 | Aveo Pharmaceuticals Inc | Anti-fgfr2 antibodies |
| JP5315495B2 (ja) | 2010-09-28 | 2013-10-16 | 積水化学工業株式会社 | 抗ヒトｃｃｒ７抗体、ハイブリドーマ、核酸、ベクター、細胞、医薬組成物、並びに、抗体固定化担体 |
| US8852592B2 (en) | 2011-05-10 | 2014-10-07 | Biocare Medical, Llc | Systems and methods for anti-PAX8 antibodies |
| US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
| US9429577B2 (en) | 2012-09-27 | 2016-08-30 | Biocare Medical, Llc | Anti-uroplakin II antibodies systems and methods |
| US10502743B2 (en) | 2012-10-09 | 2019-12-10 | Konica Minolta, Inc. | Method for detecting lung squamous cell carcinoma |
| US10429390B2 (en) | 2012-12-18 | 2019-10-01 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| EP2962113B1 (en) | 2013-02-28 | 2019-04-03 | Biocare Medical, LLC | Anti-p40 antibodies systems and methods |
| DK3052522T3 (da) | 2013-10-03 | 2020-02-24 | Biocare Medical Llc | Anti-sox 10 antistofsystemer og -fremgangsmåder |
| WO2017147247A1 (en) * | 2016-02-23 | 2017-08-31 | Pires Eusebio S | Anti-sas1b antibodies and methods of use |
| US11993645B2 (en) | 2017-01-11 | 2024-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions comprising R-Spondin (RSPO) surrogate molecules |
| WO2018140821A1 (en) | 2017-01-26 | 2018-08-02 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
| BR112020015999A2 (pt) | 2018-04-06 | 2020-12-15 | Dana-Farber Cancer Institute, Inc. | Kir3dl3 como um receptor de hhla2, anticorpos anti-hhla2 e usos dos mesmos |
| AU2019301633A1 (en) | 2018-07-09 | 2021-01-28 | Surrozen Operating, Inc. | Tissue-specific Wnt signal enhancing molecules and uses |
| JP2023549854A (ja) | 2020-11-16 | 2023-11-29 | スロゼン オペレーティング， インコーポレイテッド | 肝臓特異的Ｗｎｔシグナル増強分子およびその使用 |
| CN113476601B (zh) * | 2021-08-24 | 2022-05-20 | 知佰幸细胞库(浙江)有限公司 | 干细胞细胞因子联合海藻多糖制备的药物或化妆品 |
| WO2023114847A2 (en) * | 2021-12-14 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating disease |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JPS6459878A (en) | 1987-08-31 | 1989-03-07 | Matsushita Electric Industrial Co Ltd | Semiconductor laser protective circuit |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
| EP0770628B9 (en) | 1994-07-13 | 2007-02-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| JP2002513804A (ja) | 1998-05-05 | 2002-05-14 | アドヘレックス テクノロジーズ インコーポレイテッド | 非古典的カドヘリン媒介機能を調節するための化合物および方法 |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| EA013563B1 (ru) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство |
| JP2005500018A (ja) | 2001-04-02 | 2005-01-06 | アイデック ファーマスーティカルズ コーポレイション | ＧｎＴＩＩＩと同時発現する組換え抗体 |
| AU2002309583A1 (en) | 2001-04-18 | 2002-11-05 | Protein Desing Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| JP3817587B2 (ja) * | 2001-09-04 | 2006-09-06 | 学校法人慶應義塾 | 天疱瘡モノクローナル抗体 |
| AU2003242024A1 (en) | 2002-06-05 | 2003-12-22 | Chugai Seiyaku Kabushiki Kaisha | Method of constructing antibody |
| DE102004023187A1 (de) * | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| US20060057559A1 (en) * | 2004-06-23 | 2006-03-16 | Rigel Pharmaceuticals, Inc. | High-throughput cell migration screening assay |
| EP1829961A4 (en) | 2004-12-22 | 2008-06-04 | Chugai Pharmaceutical Co Ltd | PROCESS FOR PREPARING ANTIBODY USING A CELL WHOSE FUCOSE CARRIER FUNCTION IS INHIBITED |
| EP3111955B1 (en) | 2006-08-14 | 2019-01-23 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |
-
2007
- 2007-08-14 EP EP16178652.0A patent/EP3111955B1/en active Active
- 2007-08-14 EP EP07792477.7A patent/EP2050466B1/en active Active
- 2007-08-14 US US12/308,695 patent/US20100092457A1/en not_active Abandoned
- 2007-08-14 BR BRPI0713086-4A patent/BRPI0713086A2/pt not_active Application Discontinuation
- 2007-08-14 WO PCT/JP2007/065834 patent/WO2008020586A1/ja not_active Ceased
- 2007-08-14 CA CA002658050A patent/CA2658050A1/en not_active Withdrawn
- 2007-08-14 JP JP2008529863A patent/JP5317697B2/ja active Active
- 2007-08-14 EP EP12173653.2A patent/EP2548576B1/en active Active
- 2007-08-14 AU AU2007285217A patent/AU2007285217B2/en not_active Expired - Fee Related
-
2013
- 2013-03-05 JP JP2013043041A patent/JP5651726B2/ja active Active
-
2014
- 2014-08-29 JP JP2014175480A patent/JP5972325B2/ja active Active
-
2016
- 2016-07-12 JP JP2016137228A patent/JP6162864B2/ja active Active
-
2017
- 2017-02-10 US US15/430,031 patent/US10696743B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016185981A5 (OSRAM) | ||
| JP2017176174A5 (OSRAM) | ||
| JP2017114866A5 (OSRAM) | ||
| JP2020022464A5 (OSRAM) | ||
| JP2018504907A5 (OSRAM) | ||
| JP2016196468A5 (OSRAM) | ||
| JP2014205674A5 (OSRAM) | ||
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| MX392340B (es) | Anticuerpo anti cd73 humana. | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| JP2013539361A5 (OSRAM) | ||
| JP2013539454A5 (OSRAM) | ||
| JP2012116856A5 (OSRAM) | ||
| JP2012126742A5 (OSRAM) | ||
| JP2014012688A5 (OSRAM) | ||
| JP2020500538A5 (OSRAM) | ||
| JP2012143232A5 (OSRAM) | ||
| CL2012002095A1 (es) | Polipéptido de unión biparatópico que comprende un primer dominio variable individual de inmunoglobulina (ig) que se une específicamente a un primer epítopo del péptido ß-amiloide (ßa) y un segundo dominio variable de ig que se une específicamente a un segundo epítopo del ßa, donde dichos epítopos del ßa no son idénticos; ácido nucleico que lo codifica; vector; célula hospedera; composición farmacéutica; método de preparación; y su uso en el tratamiento y/o prevención de depósitos del ßa | |
| JP2012502649A5 (OSRAM) | ||
| JP2013538057A5 (OSRAM) | ||
| JP2017534262A5 (OSRAM) | ||
| JP2011526480A5 (OSRAM) | ||
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| JP2016116527A5 (OSRAM) | ||
| NZ630847A (en) | Anti-sema4d antibodies and epitopes |